Human Infection Challenge with Serotype 3 Pneumococcus.
Journal article
Robinson RE. et al, (2022), Am J Respir Crit Care Med, 206, 1379 - 1392
Airway-resident T cells from unexposed individuals cross-recognize SARS-CoV-2.
Journal article
Diniz MO. et al, (2022), Nat Immunol
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
Journal article
Shaw RH. et al, (2022), Lancet Respir Med
Streptococcus pneumoniae colonization associates with impaired adaptive immune responses against SARS-CoV-2.
Journal article
Mitsi E. et al, (2022), J Clin Invest, 132
Airway-resident functional T cell responses against SARS-CoV-2 in unexposed individuals
Preprint
Maini M. et al, (2022)
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Journal article
Stuart ASV. et al, (2022), Lancet, 399, 36 - 49
AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific TH1 response with a diverse TCR repertoire.
Journal article
Swanson PA. et al, (2021), Sci Transl Med, 13
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.
Journal article
Feng S. et al, (2021), Nat Med, 27, 2032 - 2040
Microbiota and compartment matter in the COVID-19 response.
Journal article
Jochems SP. et al, (2021), Nat Immunol, 22, 1350 - 1352
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Journal article
Liu X. et al, (2021), Lancet, 398, 856 - 869
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Journal article
Emary KRW. et al, (2021), Lancet, 397, 1351 - 1362
Experimental Human Pneumococcal Colonization in Older Adults Is Feasible and Safe, Not Immunogenic.
Journal article
Adler H. et al, (2021), Am J Respir Crit Care Med, 203, 604 - 613
Pneumococcal colonization impairs mucosal immune responses to live attenuated influenza vaccine.
Journal article
Carniel BF. et al, (2021), JCI Insight, 6
The influence of pneumococcal conjugate vaccine-13 on nasal colonisation in a controlled human infection model of pneumococcal carriage in Malawi: a double-blinded randomised controlled trial protocol.
Journal article
Morton B. et al, (2021), Wellcome Open Res, 6
Upper airways colonisation of Streptococcus pneumoniae in adults aged 60 years and older: A systematic review of prevalence and individual participant data meta-analysis of risk factors.
Conference paper
Smith EL. et al, (2020), J Infect, 81, 540 - 548
Symptoms associated with influenza vaccination and experimental human pneumococcal colonisation of the nasopharynx.
Journal article
Hales C. et al, (2020), Vaccine, 38, 2298 - 2306
Phase variation in pneumococcal populations during carriage in the human nasopharynx.
Journal article
De Ste Croix M. et al, (2020), Sci Rep, 10
Nasal Pneumococcal Density Is Associated with Microaspiration and Heightened Human Alveolar Macrophage Responsiveness to Bacterial Pathogens.
Journal article
Mitsi E. et al, (2020), Am J Respir Crit Care Med, 201, 335 - 347
Pneumococcal colonisation is an asymptomatic event in healthy adults using an experimental human colonisation model.
Journal article
Trimble A. et al, (2020), PLoS One, 15